Abstract: The present invention provides a therapeutic agent and a therapeutic method for cancer, etc., capable of exerting a more potent and sustained antitumor effect than existing FGFR4-selective tyrosine kinase inhibitors. The present invention is directed to a pharmaceutical combination for the treatment of cancer, characterized by comprising: a substance which inhibits or suppresses the tyrosine kinase activity of fibroblast growth factor receptor 4 (FGFR4), or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof; and an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.

Abstract: The present invention provides a therapeutic agent and a therapeutic method for hepatocellular carcinoma, etc., capable of exerting a more potent and sustained antitumor effect than existing multikinase inhibitors. The present invention is directed to a pharmaceutical combination for treating hepatocellular carcinoma, which is characterized by comprising lenvatinib or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof, and an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.